UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Conference Call March 14, 2024 10:00 AM ET

Company Participants

Vincent Perrone - Head of IR

Elizabeth Barrett - President and CEO

Mark Schoenberg - Chief Medical Officer

Dong Kim - CFO

Jeffrey Bova - Chief Commercial Officer

Silvio Pacheco - VP of Market Access

Conference Call Participants

Tara Bancroft - TD Cowen

Leland Gershell - Oppenheimer

Paul Choi - Goldman Sachs

Matt Kaplan - Ladenburg Thalmann

Operator

Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the UroGen Pharma Full Year 2023 Earnings Call. Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Vincent Perrone, Head of Investor Relations. You may begin.

Vincent Perrone

Thank you, operator. Good morning, everyone, and welcome to UroGen Pharma's full year 2023 financial results and business update conference call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter and year ended December 31, 2023. The press release can be accessed on the Investors portion of our website at investors.urogen.com.

Joining me on the call today are Liz Barrett, President and Chief Executive Officer; Dr. Mark Schoenberg, Chief Medical Officer; Jeff Bova, Chief Commercial Officer; and Don Kim, Chief Financial Officer.

During today's call, we will be making certain forward-looking statements. These may include statements regarding our ongoing commercialization activities related to JELMYTO, our ongoing and planned clinical trials, commercial and clinical milestones, market and revenue projections and opportunities, our commercialization strategy and expectation as well as potential future commercialization activities for UGN-102, if approved, anticipated data, regulatory filings and decisions, including UGN-102 potentially receiving a priority review UGN-102 being transformative and the major growth driver for UroGen have approved, future research and development efforts for UGN-103, UGN-104 and UGN-301, our corporate goals and 2024 financial guidance, among other things.

These forward-looking statements are based on current information assumptions and expectations that are subject to change. A description of potential risks can be found in our earnings press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements, and UroGen disclaims any obligation to update these statements.

I'll now turn the call over to Liz. Liz?

Elizabeth Barrett

Thanks, Vincent, and thank you to everyone joining us this morning.